Protiva Biotherapeutics, a Seattle-based biotechnology company focused on pharmaceutical products to fight against cancer, metabolic and infectious disease, has secured convertible debenture financing to the tune of $3.3 million from GrowthWorks Capital, BDC Capital, Kinetic Capital and the Canadian Medical Discoveries Fund.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.